Out of the Gate: QLT climbs after RBC upgrades
By
Associated Press
April 24, 2008
|
Shares of QLT Inc. rose Thursday after an RBC Capital Markets analyst upgraded the drug maker, saying it is underpriced given a recent divestiture and positive developments for an acne drug.
Douglas Miehm raised QLT to "Outperform" from "Sector Perform" in a note to investors on Thursday and reiterated his $6 target price.
Miehm says the Vancouver, Canada, company has several "milestones" ahead in 2008, including a divestiture of its U.S. operations. In addition, the analyst said other developments, including a recent label change to its acne drug Aczone and recent asset sales, have not been factored into the share price.
QLT shares are up 12 cents, or 3.2 percent, to $3.92. The company is scheduled to report second-quarter earnings on Friday.